Do analysts rate LFVN or GRDX?

Lifevantage presently has a consensus target price of $5.00, indicating a potential downside of 23.78%. Given Lifevantage's stronger consensus rating and higher probable upside, equities analysts plainly believe Lifevantage is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lifevantage 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer GRDX or CGTX?

Cognition Therapeutics has a consensus target price of $3.33, indicating a potential upside of 196.30%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cognition Therapeutics is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cognition Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is GRDX or CGTX more profitable?

Entero Therapeutics' return on equity of -49.81% beat Cognition Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Entero Therapeutics N/A -49.81% -11.02% Cognition Therapeutics N/A -72.68% -53.07%

Do analysts prefer ZYBT or GRDX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, ZYBT or GRDX?

Entero Therapeutics has lower revenue, but higher earnings than Zhengye Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $16.64M 5.84 -$9.98M N/A N/A Entero Therapeutics $74.46K 268.13 -$6.39M -$1.88 N/A

Is ZYBT or GRDX more profitable?

Zhengye Biotechnology's return on equity of 0.00% beat Entero Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Zhengye Biotechnology N/A N/A N/A Entero Therapeutics N/A -49.81% -11.02%

Do analysts rate GRDX or TELO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is GRDX or TELO more profitable?

Entero Therapeutics' return on equity of -49.81% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Entero Therapeutics N/A -49.81% -11.02% Telomir Pharmaceuticals N/A -201.23% -172.71%

Do analysts prefer GRDX or FRMM?

Forum Markets has a consensus target price of $10.00, suggesting a potential upside of 64.04%. Given Forum Markets' stronger consensus rating and higher possible upside, analysts plainly believe Forum Markets is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Forum Markets 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is GRDX or FRMM more profitable?

Entero Therapeutics' return on equity of -49.81% beat Forum Markets' return on equity. Company Net Margins Return on Equity Return on Assets Entero Therapeutics N/A -49.81% -11.02% Forum Markets N/A -242.09% -135.46%

Entero Therapeutics (GRDX) Competitors

$2.88 +0.11 (+3.97%)

Closing price 04:00 PM Eastern

Extended Trading

$2.88 0.00 (-0.17%)

As of 04:10 PM Eastern

Compare

GRDX vs. LFVN, CGTX, ZYBT, TELO, and FRMM

Should you buy Entero Therapeutics stock or one of its competitors? MarketBeat compares Entero Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Entero Therapeutics include Lifevantage (LFVN), Cognition Therapeutics (CGTX), Zhengye Biotechnology (ZYBT), Telomir Pharmaceuticals (TELO), and Forum Markets (FRMM).

How does Entero Therapeutics compare to Lifevantage?

Lifevantage (NASDAQ:LFVN) and Entero Therapeutics (NASDAQ:GRDX) are related small-cap companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

Lifevantage has a net margin of 2.94% compared to Entero Therapeutics' net margin of 0.00%. Lifevantage's return on equity of 23.89% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifevantage	2.94%	23.89%	12.47%
Entero Therapeutics	N/A	-49.81%	-11.02%

In the previous week, Lifevantage had 3 more articles in the media than Entero Therapeutics. MarketBeat recorded 3 mentions for Lifevantage and 0 mentions for Entero Therapeutics. Lifevantage's average media sentiment score of 0.64 beat Entero Therapeutics' score of 0.00 indicating that Lifevantage is being referred to more favorably in the media.

Company	Overall Sentiment
Lifevantage	Positive
Entero Therapeutics	Neutral

Lifevantage has higher revenue and earnings than Entero Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifevantage	$228.53M	0.36	$9.81M	$0.45	14.58
Entero Therapeutics	$74.46K	268.13	-$6.39M	-$1.88	N/A

Lifevantage presently has a consensus target price of $5.00, indicating a potential downside of 23.78%. Given Lifevantage's stronger consensus rating and higher probable upside, equities analysts plainly believe Lifevantage is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

35.3% of Lifevantage shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 22.0% of Lifevantage shares are owned by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Lifevantage has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.86, suggesting that its stock price is 86% more volatile than the broader market.

Summary

Lifevantage beats Entero Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Entero Therapeutics compare to Cognition Therapeutics?

Entero Therapeutics (NASDAQ:GRDX) and Cognition Therapeutics (NASDAQ:CGTX) are related small-cap companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Entero Therapeutics has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

Entero Therapeutics' return on equity of -49.81% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-49.81%	-11.02%
Cognition Therapeutics	N/A	-72.68%	-53.07%

In the previous week, Cognition Therapeutics had 1 more articles in the media than Entero Therapeutics. MarketBeat recorded 1 mentions for Cognition Therapeutics and 0 mentions for Entero Therapeutics. Cognition Therapeutics' average media sentiment score of 0.45 beat Entero Therapeutics' score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Entero Therapeutics	Neutral
Cognition Therapeutics	Neutral

12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by insiders. Comparatively, 11.1% of Cognition Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Entero Therapeutics has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	$74.46K	268.13	-$6.39M	-$1.88	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A

Cognition Therapeutics has a consensus target price of $3.33, indicating a potential upside of 196.30%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cognition Therapeutics is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Cognition Therapeutics beats Entero Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Entero Therapeutics compare to Zhengye Biotechnology?

Zhengye Biotechnology (NASDAQ:ZYBT) and Entero Therapeutics (NASDAQ:GRDX) are related small-cap companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Entero Therapeutics has lower revenue, but higher earnings than Zhengye Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	5.84	-$9.98M	N/A	N/A
Entero Therapeutics	$74.46K	268.13	-$6.39M	-$1.88	N/A

Zhengye Biotechnology has a beta of -2.72, meaning that its share price is 372% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.86, meaning that its share price is 86% more volatile than the broader market.

12.3% of Entero Therapeutics shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Zhengye Biotechnology had 3 more articles in the media than Entero Therapeutics. MarketBeat recorded 3 mentions for Zhengye Biotechnology and 0 mentions for Entero Therapeutics. Zhengye Biotechnology's average media sentiment score of 0.66 beat Entero Therapeutics' score of 0.00 indicating that Zhengye Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Zhengye Biotechnology	Positive
Entero Therapeutics	Neutral

Zhengye Biotechnology's return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Entero Therapeutics	N/A	-49.81%	-11.02%

Summary

Zhengye Biotechnology beats Entero Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Entero Therapeutics compare to Telomir Pharmaceuticals?

Entero Therapeutics (NASDAQ:GRDX) and Telomir Pharmaceuticals (NASDAQ:TELO) are related small-cap companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Entero Therapeutics' return on equity of -49.81% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-49.81%	-11.02%
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

Entero Therapeutics has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.24, indicating that its share price is 124% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Entero Therapeutics' average media sentiment score of 0.00 equaled Telomir Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Entero Therapeutics	Neutral
Telomir Pharmaceuticals	Neutral

12.3% of Entero Therapeutics shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by company insiders. Comparatively, 16.4% of Telomir Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Entero Therapeutics has higher revenue and earnings than Telomir Pharmaceuticals. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	$74.46K	268.13	-$6.39M	-$1.88	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

Summary

Entero Therapeutics beats Telomir Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Entero Therapeutics compare to Forum Markets?

Entero Therapeutics (NASDAQ:GRDX) and Forum Markets (NASDAQ:FRMM) are related small-cap companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

In the previous week, Entero Therapeutics' average media sentiment score of 0.00 equaled Forum Markets'average media sentiment score.

Company	Overall Sentiment
Entero Therapeutics	Neutral
Forum Markets	Neutral

Forum Markets has a consensus target price of $10.00, suggesting a potential upside of 64.04%. Given Forum Markets' stronger consensus rating and higher possible upside, analysts plainly believe Forum Markets is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Entero Therapeutics has higher earnings, but lower revenue than Forum Markets. Entero Therapeutics is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	$74.46K	268.13	-$6.39M	-$1.88	N/A
Forum Markets	$6.55M	12.46	-$450.52M	-$36.07	N/A

Entero Therapeutics has a beta of 1.86, meaning that its share price is 86% more volatile than the broader market. Comparatively, Forum Markets has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market.

12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 4.1% of Forum Markets shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by insiders. Comparatively, 25.2% of Forum Markets shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Entero Therapeutics' return on equity of -49.81% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-49.81%	-11.02%
Forum Markets	N/A	-242.09%	-135.46%

Summary

Entero Therapeutics and Forum Markets tied by winning 7 of the 14 factors compared between the two stocks.

Get Entero Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRDX vs. The Competition

Export

Metric	Entero Therapeutics	Software Industry	Technology Sector	NASDAQ Exchange
Market Cap	$19.97M	$15.46B	$29.58B	$12.85B
Dividend Yield	N/A	3.43%	2.74%	9.78%
P/E Ratio	-1.54	132.04	81.36	25.44
Price / Sales	268.13	1,298.12	598.32	80.57
Price / Cash	N/A	45.71	50.76	50.79
Price / Book	0.39	6.62	9.17	6.06
Net Income	-$6.39M	$438.13M	$663.37M	$348.34M
7 Day Performance	-5.31%	2.53%	3.87%	3.00%
1 Month Performance	-35.10%	-0.81%	-1.89%	-3.07%
1 Year Performance	N/A	6.62%	150.01%	20.68%

Entero Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRDX Entero Therapeutics	N/A	$2.89 +4.3%	N/A	N/A	$19.97M	$74.46K	N/A	9	Positive News Gap Up
LFVN Lifevantage	2.4168 of 5 stars	$6.53 +4.1%	$5.00 -23.4%	-50.4%	$82.38M	$228.53M	14.51	260	News Coverage
CGTX Cognition Therapeutics	2.0709 of 5 stars	$0.92 -4.2%	$3.33 +262.5%	+48.0%	$82.29M	N/A	N/A	20	Gap Up
ZYBT Zhengye Biotechnology	0.7621 of 5 stars	$1.73 -3.9%	N/A	-59.0%	$81.99M	$116.36M	N/A	278	Gap Down
TELO Telomir Pharmaceuticals	0.1137 of 5 stars	$1.15 -0.9%	N/A	-35.5%	$79.09M	N/A	N/A	1

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRDX) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entero Therapeutics (GRDX) Competitors

GRDX vs. LFVN, CGTX, ZYBT, TELO, and FRMM

How does Entero Therapeutics compare to Lifevantage?

Summary

How does Entero Therapeutics compare to Cognition Therapeutics?

Summary

How does Entero Therapeutics compare to Zhengye Biotechnology?

Summary

How does Entero Therapeutics compare to Telomir Pharmaceuticals?

Summary

How does Entero Therapeutics compare to Forum Markets?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRDX vs. The Competition

Entero Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entero Therapeutics (GRDX) Competitors

GRDX vs. LFVN, CGTX, ZYBT, TELO, and FRMM

How does Entero Therapeutics compare to Lifevantage?

Is LFVN or GRDX more profitable?

Does the media favor LFVN or GRDX?

Which has stronger valuation and earnings, LFVN or GRDX?

Do analysts rate LFVN or GRDX?

Do institutionals & insiders have more ownership in LFVN or GRDX?

Which has more volatility & risk, LFVN or GRDX?

Summary

How does Entero Therapeutics compare to Cognition Therapeutics?

Which has more risk and volatility, GRDX or CGTX?

Is GRDX or CGTX more profitable?

Does the media refer more to GRDX or CGTX?

Do insiders and institutionals believe in GRDX or CGTX?

Which has stronger earnings and valuation, GRDX or CGTX?

Do analysts prefer GRDX or CGTX?

Summary

How does Entero Therapeutics compare to Zhengye Biotechnology?

Do analysts prefer ZYBT or GRDX?

Which has stronger earnings & valuation, ZYBT or GRDX?

Which has more risk and volatility, ZYBT or GRDX?

Do insiders and institutionals believe in ZYBT or GRDX?

Does the media favor ZYBT or GRDX?

Is ZYBT or GRDX more profitable?

Summary

How does Entero Therapeutics compare to Telomir Pharmaceuticals?

Is GRDX or TELO more profitable?

Which has more risk and volatility, GRDX or TELO?

Do analysts rate GRDX or TELO?

Does the media refer more to GRDX or TELO?

Do institutionals & insiders believe in GRDX or TELO?

Which has preferable valuation and earnings, GRDX or TELO?

Summary

How does Entero Therapeutics compare to Forum Markets?

Does the media favor GRDX or FRMM?

Do analysts prefer GRDX or FRMM?

Which has higher earnings & valuation, GRDX or FRMM?

Which has more volatility and risk, GRDX or FRMM?

Do insiders and institutionals have more ownership in GRDX or FRMM?

Is GRDX or FRMM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRDX vs. The Competition

Entero Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools